BridgeMD
Tests treatment safety and results for Cerebrovascular Accident (CVA)
Official title Effectiveness of Enhanced External Counterpulsation for Post-acute Stroke Patients
ClinicalTrials.gov ID: NCT06711003
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn if there benefits combine enhanced external counterpulsation (EECP) with the standard post-acute care (PAC) rehabilitation treatment to treat stroke patients.. The main questions it aims to answer are: What is the feasibility of combining EECP and PAC?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 and older
You may be able to join if
- Patients with acute cerebrovascular disease, within 1 month after acute attack.
- Stable medical condition: (1). Neurological condition: The neurological condition has not deteriorated for more than 72 hours. (2). Vital signs...
- Those whose functional status is moderate to moderately severe functional impairment (MRS 3-4) and who are judged by the medical team to have active...
- Aged over 20 years old
You likely can't join if
- Patients with atrial fibrillation/arrhythmia.
- Within 2 weeks after cardiac catheterization or arterial puncture at the femoral artery puncture site.
- Decompensated heart failure (NYHA class 3 or 4).
- Left ventricular ejection fraction (EF) \< 30%.
- Moderate or severe aortic regurgitation.
- Persistent and uncontrolled hypertension (blood pressure persistently \>160/100 mmHg).
See the full eligibility criteria
- Patients with acute cerebrovascular disease, within 1 month after acute attack.
- Stable medical condition: (1). Neurological condition: The neurological condition has not deteriorated for more than 72 hours. (2). Vital signs including blood pressure, heartbeat, and body temperature are stable or...
- Those whose functional status is moderate to moderately severe functional impairment (MRS 3-4) and who are judged by the medical team to have active rehabilitation potential: (1). Have basic cognition, learning ability...
- Aged over 20 years old
- Patients with atrial fibrillation/arrhythmia.
- Within 2 weeks after cardiac catheterization or arterial puncture at the femoral artery puncture site.
- Decompensated heart failure (NYHA class 3 or 4).
- Left ventricular ejection fraction (EF) \< 30%.
- Moderate or severe aortic regurgitation.
- Persistent and uncontrolled hypertension (blood pressure persistently \>160/100 mmHg).
- Bleeding tendency.
- Active phlebitis/venous disease of the lower extremities.
- Severe vascular occlusive disease of the lower extremities.
- The presence of documented aortic aneurysm/dissection requiring surgical repair.
- Pregnancy.
The study team makes the final eligibility decision.
Where it's taking place
- Taichung, Taiwan
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taichung, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.